Zumutor Biologics develops immuno-oncology therapies that harness the body's innate immune system to treat cancer.
Zumutor Biologics has raised $7.3M in total funding. The most recent round was Series B. The last funding was announced in June 2026.
Zumutor Biologics's investors include Raj Dandu, Accel, Chiratae Ventures, Bharat Innovation Fund, Ashish Kacholia.
Zumutor Biologics is headquartered in Woburn, United States.
Zumutor Biologics develops immuno-oncology therapies that harness the body's innate immune system to treat cancer.
Zumutor Biologics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Zumutor Biologics — Funding & Investors." VCBacked, June 13, 2026, https://www.vcbacked.co/company/zumutor-biologics. Accessed September 30, 2026.
VCBacked. (2026). Zumutor Biologics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/zumutor-biologics
{{cite web |title=Zumutor Biologics — Funding & Investors |url=https://www.vcbacked.co/company/zumutor-biologics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated